author-photo

David E. Darden

9

Papers

175

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

UPDATED SAFETY AND EFFICACY RESULTS OF PHASE 1/2 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN TREATMENT-NAIVE ACUTE MYELOID LEUKEMIA PATIENTS AGED >= 65 YEARS AND UNFIT FOR STANDARD INDUCTION THERAPY

2017
Show All
- Source
- Cite
- Save
Citations (3)
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (27)
The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study

2012 Blood
Show All
- Source
- Cite
- Save
Citations (8)
The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

2012 Blood
Show All
- Source
- Cite
- Save
Citations (40)